Loading clinical trials...

An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers | Clinical Trials | Clareo Health

Back to search

COMPLETEDPHASE1

An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

NCT00918606•Neothetics, Inc

View on ClinicalTrials.gov

Summary

An Evaluation of the PK and Safety of LIPO-102 in Healthy Volunteers.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Male and non pregnant female
•18-55 years old
•Sufficient abdominal fat for injections
•Signed informed consent

Exclusion Criteria

•Known hypersensitivity to study drugs
•Treatment with an investigational agent within 30 days before first dose

Locations (1)

Baltimore, Maryland, United States

Key Dates

Start Date

February 1, 2009

Primary Completion Date

June 1, 2009

Completion Date

June 1, 2009

Last Updated

March 24, 2015

Enrollment

ACTUAL participants

Conditions

Subcutaneous Adipose Tissue Reduction

Interventions

LIPO-102

DRUG

Dose Ranging Study

NCT01802723

Periumbilical Subcutaneous Adipose Tissue Reduction

View study

COMPLETEDPHASE2

Dose Ranging and Dose Frequency of LIPO-102

NCT00918814

Subcutaneous Adipose Tissue Reduction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 24, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions